Elevate Patient Outcomes & Quality Of Life Through Collaborative Stakeholder & Advocacy Partnerships & Truly Centre The Patient Voice To

Drive New Innovation & Strengthen Impact With Advanced, Practical, Progressive & Value-Adding Strategies For Patient Centricity, Engagement & Collaboration

7th Annual One-Day, Industry-Led Conference & Networking Exhibition, One America Square, Central London, 25th June 2025

REGISTRATION OPENS

08.15 Registration & Informal Networking

OPENING REMARKS

09.00 GIC Welcome & Morning Co-Chairs’ Opening Remarks

Dr Anthony Cunliffe, Lead Medical Adviser, Macmillan Cancer Support

Gunnar Philipp, Head of Medical Affairs Europe Major Markets & Canada, CSL Behring

PATIENTS & DECISION-MAKING

09.10 Proactive & Practical Patient Empowerment Strategies Which Enable Patients To Actively Drive Their Healthcare Journeys & Make Informed Decisions

  • Patients who actively participate in decision making have better health outcomes and satisfaction, so how can we empower patients to take a more active role in their healthcare decisions, especially in complex or life-changing situations?
  • How can we help HCPs better support patients in understanding their treatment options and explore the shift towards shared decision-making and what it means for both patients and clinicians?
  • How do we create an environment where patients feel capable and confident in making decisions which align with their needs, values and goals?

Debra Montague, Founder & Chairwoman, ALK Positive Lung Cancer UK

DOUBLE PERSPECTIVE

PATIENT ADVOCACY COMMUNICATION & COLLABORATION

09.30 Build Long-Lasting Trust & Enhance Relationships Between Pharma, Healthcare Providers, Patients & Advocates For Mutually-Beneficial Partnerships That Drive Engagement & Improve Outcomes

  • Effective communication between pharma, healthcare providers, and patient advocates is essential for improving patient care, but how can it be achieved?
  • Explore innovative ways pharma companies can collaborate with patient groups to build trust and ensure accurate information flow
  • Poor communication can lead to confusion, mistrust, and missed opportunities to improve patient outcomes, so how can pharma better support patient advocacy groups and help them amplify their voices in healthcare discussions?

09.30 Perspective 1

Phillip Ho, Global Vaccines Public Affairs, Sanofi Pasteur

Vinny Smith, Chief Executive, Meningitis Research Foundation

09.50 Perspective 2

Mary Lynne van Poelgeest-Pomfret, President, WFIPP

PANEL Q&A

PATIENT REPRESENTATION & INCLUSION IN CLINICAL TRIALS

10.10 Design Patient-Centric Clinical Trials Which Drive Engagement, Recruitment & Positive Patient Experiences & Ensure Equitable Patient Representation & Inclusion

  • Explore brand new strategies to improve diversity in clinical trials, considering all factors from age, ethnicity, and socioeconomic in order to truly reflect diverse experiences
  • Embed the patient voice in trial design processes to ensure their needs and requirements are integrated into trials from the very start
  • From access issues to biases, pinpoint exactly what’s preventing true inclusivity in clinical trials, and how we can overcome these challenges in 2025 and beyond
  • Hear first-hand how patient groups are working alongside pharma companies to address disparities and create trial designs which include and benefit everyone

John Ioannou, VP, Global Medical Head of Immunology Therapeutic Area, UCB

Anisha Lad, Senior Medical Affairs Advisor – Oncology, Pfizer

Sumair Nizamuddin, Paediatric Impact & Engagement Manager, Experimental Cancer Medicine Centres, Cancer Research UK

10.40 Bonus Session; Reserved For Fixing us

Rohin Malhortra, Managing Director, Fixing us

10.55 Morning Refreshment Break & Informal Networking

11.25 Bonus Session; Reserved For Exclusive Conference Partner

INTERACTIVE DELEGATE DISCUSSION

AI, NEW TECH & INNOVATION IN HEALTHCARE

11.40 Utilise AI & New, Innovative Technologies To Improve Patient Care – Compliantly – Without Losing The Critical Human Touch

  • AI, AI, AI, it’s everywhere we know, but is it really possible for AI and new tech to enhance patient care while maintaining an authentic personal touch?
  • How can we evidence systems are reliable and beneficial to build patient trust in new tech and AI to ensure they are interacting with value-add services
  • Industry benchmarking: what role will AI and digital technologies play in the future of patient care?
  • Explore the new opportunities and challenges which come alongside integrating AI into diagnostics, treatment, and patient management

PANEL Q&A
HEAR FROM THE PATIENTS THEMSELVES

PATIENT PERSPECTIVES IN TREATMENT – QUALITY OF LIFE

12.00 Prioritise Quality Of Life In Treatment Decisions For All Patients By Building Holistic Healthcare Systems Around Patient Needs & Expectations

  • What do patients really want, and expect, from Pharma to advance advocacy objectives and truly improve holistic patient quality of life in 2025 and beyond?
  • As life expectancy increases, older populations are increasingly focused on quality of life rather than just longevity, so how can healthcare systems respond appropriately to this shift?
  • There’s a growing need for holistic care that considers both physical and mental health, beyond just prolonging life. How can we address the emotional and cognitive effects of chronic conditions while ensuring patients still receive effective care?

Mary Lynne van Poelgeest-Pomfret, President, WFIPP

Juddy Otti, GROWS Lead, Sophia Forum UK

BARRIERS TO PATIENT CENTRICITY

12.30 Overcome Persistent Internal & External Barriers To Patient Centricity To Achieve Real Change & Ensure All Teams Are Moving In The Same Direction

  • Despite the push for patient-centric care, many organisations still face significant internal and external barriers to true engagement. Discover new, proven and successful strategies to overcome these barriers and foster true patient-centric cultures
  • How can companies integrate patient feedback throughout the entire healthcare process, from clinical trials to treatment?
  • Explore how organisational processes, compliance issues, and resource gaps can prevent effective patient involvement in order to mitigate barriers and areas of resistance

Ravindra Deore, Senior Medical Director, Global Medical Affairs, Mundipharma

PANEL Q&A

PATIENT INVOLVEMENT IN HTA

12.50 Champion PAGs & Amplify Patient Voices In Health Technology Assessments For More Equitable Healthcare Decisions

  • What are the most effective ways to involve patients in HTA and how can we quantify that positive impact on equitable healthcare policies and real-world patient needs?
  • What are the barriers preventing effective patient involvement in HTAs, and how can we overcome them? Hear about the positive outcomes when patient representatives successfully influence HTA decisions in Europe and beyond
  • How can patient representatives impact HTA processes to ensure that treatments are evaluated from the patient’s perspective?

Michal Davidescu, Market Access Specialist – Launch Strategy & MOH Relations, Pfizer

Matthijs van Meerveld, Global Head of Access Policy & Patient Advocacy, Oncology, Menarini Stemline

13.20 Lunch & Informal Networking For Speakers, Delegates & Partners

OPENING REMARKS

14.20 Afternoon Co-Chairs’ Opening Remarks

Dr Rick Lones, VP, Global Head of Medical Affairs, Mundipharma

Pam Jayia, Associate Group Medical Director, Clinical Safety, Roche

PANEL Q&A

STAKEHOLDER COLLABORATION

14.30 Break Down Siloes To Increase Multi-Stakeholder Collaboration, Better Respond To Patient Needs & Improve Outcomes

  • Pharmaceutical companies, healthcare providers and patient groups often work in silos but how can we unite complex stakeholder networks across healthcare to align behind goals and improve patient care?
  • Uncover how organisations are already bridging gaps between stakeholders to improve communication and transparency – compliantly
  • What role can pharma play in supporting patient groups’ advocacy and operational capacity to achieve better patient outcomes, faster treatment access and more personalised care?

Mary Lynne van Poelgeest-Pomfret, President,WFIPP

Melanie Costin, Interim Chief Executive Officer, Fight Bladder Cancer

PATIENT ADVOCACY COMMUNICATION & COLLABORATION

15.00 Build Long-Lasting Trust & Enhance Relationships Between Pharma, Healthcare Providers, Patients & Advocates For Mutually-Beneficial Partnerships That Drive Engagement & Improve Outcomes

  • Effective communication between pharma, healthcare providers, and patient advocates is essential for improving patient care, but how can it be achieved?
  • Explore innovative ways pharma companies can collaborate with patient groups to build trust and ensure accurate information flow
  • Poor communication can lead to confusion, mistrust, and missed opportunities to improve patient outcomes, so how can pharma better support patient advocacy groups and help them amplify their voices in healthcare discussions?

Emily Burns, Patient Advocacy Lead, AstraZeneca UK

CASE STUDY

PATIENT TRUST WITH HEALTH SYSTEMS

15.20 Exclusive Case Study Around Patient Trust With Health Systems

  • Looking into patients trust in data sharing and the barriers with patients out for diagnosis and treatment
  • Deep dive into the reasons and factors involving why patients have trust issues with health systems which lead to a lack of engagementRecommendations on what can be done to improve these challenges

Sumair Nizamuddin, Paediatric Impact & Engagement Manager, Experimental Cancer Medicine Centres, Cancer Research UK

15.40 Bonus Session; Reserved For Exclusive Conference Partner

16.10 Afternoon Refreshment Break & Informal Networking

DOUBLE PERSPECTIVE

PATIENT ENGAGEMENT, VOICE & SENSITIVITY

16.40 Power End-To-End Patient Engagement By Truly Listening, Authentically Valuing & Effectively Responding To Diverse Patient Needs

  • Patient engagement increases when patients feel heard, valued, and understood, so how can we truly listen and respond to their needs?
  • Integrating the patient voice in all stages of the healthcare journey is crucial, so how can organisations ensure they are engaging patients authentically, while remaining sensitive to their diverse experiences and challenges?
  • Uncover new insights from organisations that have successfully put the patient voice at the centre of their work, demonstrably improving outcomes for all

16.40 Perspective 1

Jannike Nordlund, Programme Manager for Patient Involvement, Experience & Inequalities, South East London Cancer Alliance

17.00 Perspective 2

Lili White, Senior Communications & Campaigns Officer, MS International Federation

DIAGNOSTICS & BRAIN HEALTH - FIRESIDE CHAT

17.20 Exclusive Session With Roche Diagnostics Ltd

Ashton Harper, MD, Head of Medical Affairs (UK & Ireland), Roche Diagnostics Ltd

PROMOTING PATIENT AUTONOMY – COLLABORATING ON PERSONALISED TREATMENT PLANS

17.40 Empower Patients & Prioritise Patient Autonomy By Designing & Implementing Personalised Treatment Plans For Better Health Outcomes

  • Empowering patients to make informed decisions can lead to better health outcomes and improved patient satisfaction, so how can clinicians, pharma, and patients work together to create personalised cared plans?
  • Explore the importance of personalised treatment plans and the barriers patients face when trying to access innovative therapies
  • How can we help patients take ownership of their treatment decisions when new, adaptive therapies become available?

Helen Bulbeck, Director of Services & Policy, brainstrust

18.00 Afternoon Co-Chairs’ Closing Remarks & Close Of Conference

Dr Rick Lones, VP, Global Head of Medical Affairs, Mundipharma

Pam Jayia, Associate Group Medical Director, Clinical Safety, Roche

Don't Miss Out!

Book Before Thursday & Save £170!